Ignite Creation Date:
2024-05-06 @ 7:03 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05870748
Status:
RECRUITING
Last Update Posted:
2024-04-19
First Post:
2023-05-12
Brief Title:
REFRaME-O1 A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigators Choice IC Chemotherapy in Women With Ovarian Cancer Including Fallopian Tube or Primary Peritoneal Cancers Expressing FOLR1
Sponsor:
Organization:
Sutro Biopharma Inc